Skip to main content
Premium Trial:

Request an Annual Quote

Roche and CombiMatrix Strike Deal to Develop and Market Biochip Technology

NEW YORK, July 3 – Roche Diagnostics has entered into a 15-year agreement to purchase, use and resell CombiMatrix’s biochips, the companies announced Tuesday.

The worldwide, non-exclusive deal includes minimum payments by Roche to CombiMatrix during the first three years of the agreement, including royalties, payments for products, and R&D projects. The deal also stipulates that the companies develop a joint platform technology for standardized biochips.

Financial details of the agreement were not disclosed.

“This unique platform will be useful for multiple applications, including gene expression studies, single nucleotide polymorphism analysis, disease classification, pathway identification, and toxicology studies, Susanne Raehs, head of Roche Applied Science, said in a statement.

Acacia Research is the majority owner of Snoqualmie, Wash.-based CombiMatrix, which uses semiconductor technology to develop customizable microarrays. CombiMatrix remains registered for an initial public offering filed in November.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more